NetworkNewsBreaks – Clene Inc. (NASDAQ: CLNN) to
Post# of 174

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company developing treatments for neurodegenerative diseases such as ALS and MS, announced that its management will present at the Canaccord 45th Annual Growth Conference and participate in one-on-one investor meetings.
NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://nnw.fm/CLNN
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer

